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Rapid cancer cell proliferation promotes the production of
reducing equivalents, which counteract the effects of relatively
high levels of reactive oxygen species. Reactive oxygen species
levels increase in response to chemotherapy and cell death,
whereas an increase in antioxidant capacity can confer resis-
tance to chemotherapy and is associated with an aggressive
tumor phenotype. The pentose phosphate pathway is a major
site of NADPH production in the cell, which is used tomaintain
the main intracellular antioxidant, glutathione, in its reduced
state. Previous studies have shown that the rate of hyperpolar-
ized [1-13C]dehydroascorbic acid (DHA) reduction, which can
bemeasured in vivo using non-invasive 13Cmagnetic resonance
spectroscopic imaging, is increased in tumors and that this is
correlated with the levels of reduced glutathione.We show here
that the rate of hyperpolarized [1-13C]DHA reduction is
increased in tumors that have been oxidatively prestressed
by depleting the glutathione pool by buthionine sulfoximine
treatment. This increase was associated with a corresponding
increase in pentose phosphate pathway flux, assessed using
13C-labeled glucose, and an increase in glutaredoxin activity,
which catalyzes the glutathione-dependent reduction of
DHA. These results show that the rate of DHA reduction
depends not only on the level of reduced glutathione, but also
on the rate of NADPH production, contradicting the conclu-
sions of some previous studies. Hyperpolarized [1-13C]DHA
can be used, therefore, to assess the capacity of tumor cells to
resist oxidative stress in vivo. However, DHA administration
resulted in transient respiratory arrest and cardiac depres-
sion, which may prevent translation to the clinic.
Cancer cell proliferation promotes the production of
reducing equivalents, such as reduced glutathione (GSH)
and NADPH, which counteract the effects of relatively high
levels of reactive oxygen species (ROS)5 (1). Themost abundant
intracellular antioxidant, GSH, which is typically 0.5–10 mM,
can react with hydrogen peroxide in the reaction catalyzed by
glutathione peroxidase and can also react directly with ROS in
non-enzyme-catalyzed reactions (2). The resulting oxidized
glutathione (GSSG) is reduced byNADPH-dependent glutathi-
one reductase, which maintains it in the 5–50 M range (2). A
major source of thisNADPH is the cytosolic pentose phosphate
pathway (PPP) (3) (Fig. 1a). The redox couples GSSG/GSH and
NADP/NADPH are therefore a reflection of cell redox state,
which increase in the face of increased oxidative stress. In-
creased ROS production is often associated with chemothera-
py-induced apoptosis and is an early event in tumor responses
to treatment (4). Depletion of glutathione increases the tumor-
specific cytotoxicity of several chemotherapeutic drugswithout
increasing toxicity to normal tissues (5), and the ability of some
cancer cells to maintain a highly reduced intracellular environ-
ment has been correlated with tumor aggressiveness and drug
resistance (6).
Hyperpolarized 13C magnetic resonance spectroscopy (MRS)
and spectroscopic imaging (MRSI) have enabled real timemea-
surement of metabolic fluxes in vivo by increasing the signal-
to-noise ratio by more than 104-fold (7). The most widely used
substrate has been [1-13C]pyruvate, where the rate of hyperpo-
larized 13C label exchange between the injected labeled pyru-
vate and endogenous lactate has been shown to be a marker of
tumor grade and treatment response (8–11). The technique
was translated to the clinic recently with a trial in prostate can-
cer (12). Lactate can also become labeled following injection of
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hyperpolarized [U-2H,U-13C]glucose, and the rate of labeling
has been used to assess glycolytic flux in breast cancer cells and
yeast in vitro (13, 14) and to image glycolytic flux in EL4murine
lymphoma tumors in vivo (15). In EL4 tumors, labeling of
6-phosphogluconate (6PG), an intermediate in the PPP, was
also observed, suggesting that hyperpolarized [U-2H,U-13C]
glucose might also be used for real time assessment of NADPH
production in the PPP and therefore potentially the capability
of the tumor cells to resist oxidative stress (15, 16). Another
potential approach to assess resistance to oxidative stress is to
monitor the rate of reduction of hyperpolarized [1-13C]dehy-
droascorbic acid (DHA) to [1-13C]ascorbic acid (AA). DHA
reduction can occur spontaneously by reaction with GSH or be
catalyzed by theGSH-dependent thiol-disulfide oxidoreducta-
ses, glutaredoxin (Grx; EC 1.20.4.1) and protein-disulfide
isomerase and by theNADPH-dependent enzymes thioredoxin
reductase (TrxR; EC 1.8.1.9) and 3-hydroxysteroid dehydro-
genase (17). Reduction of hyperpolarized [1-13C]DHA to
[1-13C]AA has been detected using 13CMRS andMRSI, both in
vitro and in vivo, including in tumors (18–20), where the rate
was suggested to depend on the levels of GSH (19–21). Despite
the increase in sensitivity to MR detection afforded by hyper-
polarization, [1-13C]DHA must be used at relatively high con-
centrations, and therefore DHA is itself an oxidative stressor.
DHA has been shown previously, for example, to oxidize GSH,
to increase PPP flux (23), and to have adverse effects on the
central nervous system (24).
The aim of this study was to determine whether the rate of
hyperpolarized [1-13C]DHA reduction is dependent only on
the levels of GSH or if it also depends on PPP flux. First we
showed that DHA treatment of tumor cells in vitro produces a
similar and rapid increase in PPP flux as the oxidants hydrogen
peroxide and phenazine methosulfate (PMS), which is an
NADPH-oxidizing agent (25). We then showed that intrave-
nous administration of DHA produces a similarly rapid
increase in PPP flux in tumor cells in vivo. Changes in PPP flux
were assessed using [1,2-13C2]glucose and measuring label
incorporation into lactate in cell and tissue extracts using 13C
MRS and by measuring label incorporation from [U-13C]glu-
cose into 6PG using liquid chromatography tandemmass spec-
trometry (LC-MS/MS) (26, 27).We alsomeasured 6PG labeling
from hyperpolarized [U-2H,U-13C]glucose in tumors in vivo
using 13C MRS measurements. Next we showed that depletion
of the glutathione pool in tumor cells in vitro and tumors in
vivo, using the-glutamyl-cysteine synthetase inhibitor buthio-
nine sulfoximine (BSO) (28), led to increased PPP flux and Grx
activity and an increased rate of hyperpolarized [1-13C]DHA
reduction in two different tumor models, thus demonstrating
that the rate does not depend only on the levels of GSH. How-
ever, DHA led to transient respiratory arrest and cardiac
depression in the tumor-bearing animals. Hyperpolarized
[1-13C]AA, an alternative substrate for assessing oxidative
stress that shows no such toxicity, has been observed previously
to show no detectable oxidation in tumors (18). We show here
that its oxidation is likely to be transport-limited and depen-
dent on intracellular ROS.
Results
DHAAdministration Results in Rapid Increases in the GSSG/
GSHRatio and PPP Flux inCells andTumors—First we showed
that DHA produced the same rapid increase in PPP flux as the
oxidants hydrogen peroxide and PMS (Fig. 1a). EL4 murine
lymphoma cells were incubated for 30 min with either 50 M
PMS (25), 1 mM hydrogen peroxide (29), or 11 mM DHA (30).
Total glutathione levels and the GSSG/GSH ratio were mea-
sured by LC-MS/MS (31). Total glutathione was unchanged by
PMS and DHA treatment, but there was a small but significant
decrease following hydrogen peroxide treatment (Table 1).
With all three oxidants, there was a marked increase in the
GSSG/GSH ratio, consistentwith an increase in oxidative stress
(32). Flux into the PPPwas assessed by simultaneous incubation
with 11 mM [1,2-13C2]glucose and analysis of the labeling pat-
FIGURE1.PPP flux inoxidant-treatedEL4cells.a, DHA is reduced toAAbyGSH, catalyzedbyGrx,GST, andPDI andbyNADPH-dependent reactions catalyzed
by TrxR and 3-hydroxysteroid dehydrogenase (3-HSD). Reduction of GSSG is catalyzed by glutathione reductase (GR). 6PGL, 6-phosphogluconolactone;
6PGLase, 6-phosphogluconolactonase; LDH, lactate dehydrogenase. b–d, ratio of lactate singly labeled at C3 to the total labeled lactate concentration. Cells
were incubated for 30 min with 11 mM [1,2-13C]glucose and 50 M phenazine methosulfate (PMS) (b), 1 mM H2O2 (c), or 11 mM DHA (d). e–g, ratio of
13C to
12C-labeled 6PG in cells that were incubated for 30 s with 11mM [U-13C]glucose and had been incubated previously for 30min with 50M PMS (e), 1 mM H2O2
(f), or 11 mM DHA (g). Error bars, S.D. (n 3). *, p 0.05; **, p 0.01; ****, p 0.0001.
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tern in the resulting lactate using 13C NMR (27) (Fig. 1, b–d)
and by incubation with 11 mM [U-13C]glucose 30 min after
oxidant treatment and then 30 s later, analyzing label incorpo-
ration into 6PG using LC-MS/MS (26) (Fig. 1, e–g). Bothmeth-
ods showed a similar and rapid increase in PPP flux with all of
the oxidants.
Next we assessed the effect of DHA administration on PPP
flux in vivo. 13C MRS measurements of lactate labeling in EL4
tumor extracts from animals injected with DHA and [1,2-
13C2]glucose showed a significant increase in PPP flux as com-
pared with control tumors, although this was less evident than
in EL4 cells in vitro (Fig. 2a). However, the increase in 6PG
labeling, measured in tumor extracts in animals injected with
[U-13C]glucose (Fig. 2b) or measured using non-invasive local-
ized 13C MRS measurements in vivo in animals injected with
hyperpolarized [U-13C,U-2H]glucose (15) (Fig. 2, c and d), was
not significantly different between untreated mice and mice
injected with DHA. Unlike EL4 cells, the DHA-treated tumors
showed no change in the GSSG/GSH ratio compared with
untreated tumors; however, there was a significant increase in
the activity of the PPP enzyme, glucose-6-phosphate dehydro-
genase (G6PDH) (Table 1), consistent with an increase in oxi-
dative stress (33).
Flux of glutamine carbon via malic enzyme, to lactate, also
produces NAPDH for glutathione reduction (34). However,
tumor extracts prepared from EL4 tumor-bearing mice
injected with [3-13C]glutamine showed no significant increase
in lactate C2 and C3 labeling following DHA treatment (C2
labeling was 0.18  0.03 mol min1 g tumor1 in control
tumors (n  4) versus 0.30  0.09 mol min1 g tumor1 in
DHA-treated tumors (n 4), p 0.26).
These experiments have shown that in using DHA as a probe
of the capacity of a cell to resist oxidative stress, it results in an
increase in the GSSG/GSH ratio, as it is reduced to AA, and a
rapid increase in PPP flux. Next we asked what would happen
to the rate of DHA reduction in a tumor cell that had been
oxidatively prestressed. We chose to do this by depleting the
glutathione pool because this would also allow us to exam-
ine how the rate of DHA reduction was related to GSH
concentration.
InducingOxidative Stress inCells byGlutathioneDepletion—
BSO sensitizes tumor cells to radiotherapy (35) by depleting
glutathione (Fig. 3a) (28). Treatment of EL4 and Colo205 cells
with BSO decreased glutathione levels, although the levels of
glutathione were much higher in Colo205 cells (Table 2). In
both cell lines, there was a marked decrease in the GSSG/GSH
ratio (Table 2), indicating up-regulation of pathways responsi-
ble for maintaining glutathione in a reduced state. This can be
explained by an increase in PPP flux. At 24 h following BSO
treatment, PPP flux in EL4 cells, assessed from measurements
of lactate labeling, was increased by 1.5-fold (Fig. 3a), whichwas
increased a further2.2-fold by the addition of DHA (Fig. 3b).
13C label incorporation into 6PG was increased by more than
2-fold at 24 h after BSO treatment (n  3, p  0.0019), which
was increased a further 4-fold by the addition of DHA (n  3,
p  0.0001) (Fig. 3d). GAPDH and G6PDH activities were
unchanged; however,Grx activity increased significantly at 24 h
after BSO treatment (Table 2). In Colo205 cells, BSO treatmentTA
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for 6 h led to a significant increase in PPP flux, as assessed from
measurements of lactate labeling (Fig. 3c), but there was no
significant change in 6PG labeling (Fig. 3e). Both GAPDH and
G6PDH activities increased significantly at 24 h following BSO
treatment (Table 2). In summary, these experiments have
shown that oxidatively prestressing cells by glutathione deple-
tion results in up-regulation of the PPP and a lower steady state
GSSG/GSH ratio. DHA administration, as was shown in non
BSO-treated cells, resulted in a rapid increase in PPP flux.
Next we investigated the effects of glutathione depletion in
EL4 andColo205 tumors. BSO is clearedwithin 24 h of infusion
in mice and causes no obvious toxicity (36). In EL4 tumors 6 h
after BSO treatment, there was a significant decrease in gluta-
thione content (n 5, p 0.0013) and a 2-fold decrease in the
GSSG/GSH ratio (Table 2). By 24 h, glutathione levels had
recovered, whereas the GSSG/GSH ratio remained lower than
in controls, although this was not significant (Table 2). In ani-
mals treated 24 h previously with BSO and injected with hyper-
polarized [1-13C]DHA immediately before freeze clamping of
the tumor, glutathione levels were similar to those in control
tumors; however, the GSSG/GSH ratio was significantly higher
(n  3, p  0.048), reflecting rapid reduction of the DHA by
GSH (Table 2). Measurements of lactate labeling in tumor
extracts showed that 6 h after BSO treatment, there was a sig-
nificant increase in PPP flux compared with untreated tumors
(n 4, p 0.0051) (Fig. 3e), which was confirmed by increased
13C labeling of 6PG (Fig. 3g) at 6 and 24 h after BSO treatment.
As in the experiments on the cells in vitro, this increased PPP
flux can explain the lower GSSG/GSH ratio. Glycolytic flux
decreased from1.19 0.09 to 0.55 0.19molmin1 g1 (n
4, p 0.0009) at 6 h but increased to 0.93 0.10 mol min1
g1 (n 4, p 0.04) at 24 h after BSO treatment. At 24 h, there
FIGURE 2. PPP flux in EL4 tumors treated with DHA. EL4 tumor-bearing mice were injected with 0.4 ml of 200 mM [1,2-13C2]glucose (n 4) or 0.4 ml of 200
mM [1,2-13C2]glucose and28mMDHA (n 3). Lactate labelingwasmeasured in tissue extracts by
13CNMR.a, ratio of lactate singly labeled at C3 to total labeled
lactate. b, ratio of 13C to 12C-labeled 6PG in control (Ctrl) EL4 tumors (n 4) injected with 0.4 ml of 200 mM [U-13C]glucose and EL4 tumors injected simulta-
neouslywith 28mMDHAand 0.4ml of 200mM [U-13C]glucose (n 6). c, 13C spectrumof hyperpolarized [1-13C]lactate (185.1 ppm) and [1-13C]6PG (181.4 ppm)
in a control EL4 tumor 15 s after the start of injection of 0.4ml of 200mMhyperpolarized [U-2H,U-13C]glucose. d, untreatedmice (Ctrl, n 5) ormice pretreated
3 min earlier with 28 mM DHA (n 5) before injection of hyperpolarized [U-2H,U-13C]glucose (200 mM, 0.4 ml). The ratio of the sum of the intensities of the
[1-13C]6PG resonance to the sum of the intensities of the [1-13C]lactate resonance in the first nine spectra is shown. Error bars, S.D. **, p 0.01.
FIGURE 3. PPP flux in BSO-treated EL4 and Colo205 cells and tumors. The ratio of lactate singly labeled at C3 to total labeled lactate concentration in EL4
cells (108) (a) and Colo205 cells (107) (b) treated with 100M BSO and then incubated in RPMI medium containing 11mM [1,2-13C2]glucose with or without 11
mMDHA for 30min. EL4 (e) andColo205 (f) tumorswere treatedwith500mgkg1 BSOand injectedwith0.4mlof 200mM [1,2-13C2]glucose and freeze-clamped
4min later. Shown is the ratio of 13C- to 12C-labeled 6PG in extracts of EL4 (c) and Colo205 (d) cells treated with 100M BSO and incubated for 30 s with 11mM
[U-13C]glucose with or without 11mMDHA. Shown are EL4 (g) and Colo205 (h) tumors treated with 500mg kg1 BSO and then injected with 0.4ml of 200mM
[U-13C]glucose and freeze-clamped 1 min later. Error bars, S.D. *, p 0.05; **, p 0.01; ***, p 0.001; ****, p 0.0001.
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was increased fractional labeling of the glycolytic intermediates
3-phosphoglycerate and phosphoenolpyruvate (3PG, 11.3 
2.9% in control versus 29.9 4.6% in treated tumors, n 4, p
0.0136; PEP, 51.4  5.4% in control versus 76.2  4.3% in
treated tumors, n  4, p  0.0116). GAPDH activity was
unchanged, but there was an increase in G6PDH activity (Table
2), again indicative of oxidative stress (33) and consistent with
data indicating increased PPP flux (Fig. 3, e and g). Of the
enzymes involved in DHA reduction, Grx activity increased
24 h after BSO treatment (Table 2), as was observed in the cells,
both with (n 3, p 0.02) and without injection of DHA (n
7, p  0.045). There were no changes in the activities of TrxR
(69.4 1.0 nmol min1 mg tumor1 in control (n 6) versus
64.0  1.3 nmol min1 mg tumor1 in BSO-treated tumors
(n 5)) and GST (40 1 nmol min1 mg tumor1 in control
(n 6) versus 39 1 nmol min1 mg tumor1 in BSO-treated
tumors (n 5)).
BSO treatment of Colo205 tumors had no significant effect
on glutathione levels orGSSG/GSH ratio (Table 2). Therewere,
however, significant increases in 6PG labeling at 6 and 24h after
BSO treatment, indicating an increase in PPP flux, although this
was not reflected in lactate labeling (Fig. 3, f and h). There were
no significant changes in the activities of GAPDH, G6PDH, or
Grx (Table 2).
Detecting Oxidative Stress in BSO-treated EL4 and Colo205
Tumors Using Hyperpolarized [1-13C]Dehydroascorbic Acid—
Non-invasive 13C MR spectroscopic measurements with
hyperpolarized [1-13C]DHA were performed in the same
cohort of animals as used for GSSG/GSH and enzyme activity
measurements. A separate cohort of animals was used for mea-
surements of PPP flux. Hyperpolarized [1-13C]DHA has been
shown previously to be rapidly reduced in tumors in vivo
(18–20). Consistent with these previous observations, 13C
spectroscopic images showed a more general distribution of
[1-13C]DHA throughout the animal, whereas [1-13C]AA, pro-
duced by intracellular reduction of DHA, was localized mainly
to the tumor region (Fig. 4a). Oxidatively prestressing EL4
tumors by BSO treatment increased the rate of hyperpolarized
[1-13C]DHA reduction, which, although highly variable, was
3.8-fold higher in tumors treated 24 h previously with BSO
than in control tumors (p  0.044) (Fig. 4, b–d). At this time
point, there was no difference in total glutathione content and
GSHconcentration (Table 2) between control andBSO-treated
tumors, but therewas a significant increase in PPP flux (Fig. 3g).
13C NMR spectra of extracts prepared from these tumors,
where the tumors were freeze-clamped at 5 min after injec-
tion of the hyperpolarized [1-13C]DHA, showed that there was
70.5 40.5 nmol g1 [1-13C]DHA in 24-h BSO-treated tumors
(n  2) and 97.5  34.5 nmol g1 in control tumors (n  2).
[1-13C]AA was undetectable, although this may reflect oxida-
tion of AA during perchloric acid extraction. Assuming that
this is the concentration of [1-13C]DHA present at the time the
13C MRS measurements were made in vivo and using the
[1-13C]AA/[1-13C]DHA ratio at 30 s after injection of hyperpo-
larized [1-13C]DHA, this equates to a [1-13C]DHA reduction
rate of 0.42  0.15 and 1.43  0.82 nmol g1 s1 in control
tumors and 24-h BSO-treated tumors, respectively. In Colo205
tumors, the hyperpolarized [1-13C]DHA reduction rate at 24 hTA
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after BSO treatmentwas also highly variable, but in this case the
increase was not significant (Fig. 4c). Although in these BSO-
treated Colo205 tumors there was no measurable decrease in
the GSSG/GSH ratio, there was nevertheless a significant
increase in PPP flux (Fig. 3, f and h).
Hyperpolarized [1-13C]DHA led to transient respiratory
arrest and cardiac depression in thesemice, whichwas dose-de-
pendent (Fig. 5). Respiratory and cardiovascular effects of DHA
have been observed previously following intravenous injection
in rats (24).
DetectingOxidative Stress withHyperpolarized [1-13C]Ascor-
bic Acid—BecauseDHAhas adverse, although transient, effects
onmouse physiology, we also exploredwhether oxidative stress
could be assessed using [1-13C]AA, which is nontoxic and used
clinically in intravenous infusions (37). We had shown previ-
ously that hyperpolarized [1-13C]AA can be injected into mice
and detected in EL4 tumors (18). However, although oxidation
of hyperpolarized [1-13C]AA to [1-13C]DHA was observed in
vitro, no [1-13C]DHA was observed in EL4 tumors in vivo. One
explanation for this is that any DHA produced is rapidly re-re-
duced to AA (18). To investigate this further, we examined the
factors affecting AA oxidation. Hyperpolarized [1-13C]AA
reacted only slowly with hydrogen peroxide. Fitting the hyper-
polarized [1-13C]DHA peak intensity gave a pseudo-first order
rate constant for the oxidation of AA by 100 M H2O2 of 9 
103 s1 and, therefore, a second order rate constant of 90 M1
s1, which is similar to values measured previously (38) but is
orders ofmagnitude slower than the second order rate constant
for the reaction of AA with superoxide (39). When [1-13C]AA
was added to an EL4 tumor cell suspension, a low rate of oxida-
tion was observed (Fig. 6b), as reported previously (18). The
oxidation rate in the cell suspension was similar to that
observed in cell culture medium (RPMI) alone (Fig. 6a). How-
ever, when the cells were lysed, the rate of AA oxidation was
much higher (Fig. 6c), 2.18 mmol liter1 s1 versus 4.96 mmol
liter1 s1.
Discussion
There has been considerable interest in the development of
imaging methods that could be used to image oxidative stress
FIGURE 4. DHA reduction rate in EL4 and Colo205 tumors. a, chemical shift images of [1-13C]DHA and [1-13C]AA in an EL4 tumor-bearing mouse 27 s after
injecting 0.2 ml of 28 mM hyperpolarized [1-13C]DHA. Color intensities were normalized to the respective maxima in the images. b–e, 13C spectroscopic
measurements of DHA reduction in EL4 and Colo205 tumors treatedwith 500mg kg1 BSO and then injectedwith 0.4ml of 28mMhyperpolarized [1-13C]DHA
6 or 24 h later. Spectra were acquired 15 s after the start of injection. Representative spectra, which are the sumof the 15 spectra acquired during the first 15 s,
are shown for a control EL4 tumor (b) and an EL4 tumor 24 h after BSO treatment (c). The signal at 175.3 ppm is from [1-13C]DHA, and the signal at 179 ppm is
from [1-13C]AA. Shown is the ratio of the sum of the hyperpolarized [1-13C]DHA and [1-13C]AA signals in the first 15 s of data acquisition (15 spectra) for EL4
tumors (d) and Colo205 tumors (e). Error bars, S.D. *, p 0.05.
FIGURE5.Respiratory rate (a) andheart rate (b) ofC57BL/6mice (no injec-
tion, *) or injectedwith dissolution buffer (E) or 10 (), 25 (Œ), 50 (), or
62.5 mg kg1 (f) DHA, produced by charcoal oxidation of ascorbic acid
or 50mgkg1DHA fromSigma-Aldrich (●). Each conditionwas tested in a
separate mouse. The black lines indicate time of injection.
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and cellular redox state non-invasively in vivo (40). Glutathione
has been measured using 1H MRS (41); T1-weighted MRI and
EPR imaging of injected nitroxides have been used, in preclin-
ical studies, to assess tissue redox status (42–44); and an EPR
method thatmeasures extracellular pH, redox status, and intra-
cellular GSH concentration has been described (45). MRI
probes of ROS based on T1-shortening or chemical exchange
saturation transfer and redox-active PET tracers have also been
developed (46, 47); however, most agents are not taken up by
cells and lack sensitivity for biologically relevant redox ranges.
We have described here a dynamic 13C magnetic resonance
spectroscopymethod for imaging the capacity of tumors in vivo
to resist oxidative stress using hyperpolarized [1-13C]DHA.
We have shown that DHA acts as a cellular oxidant in cells in
vitro, producing increases in the GSSG/GSH ratio similar to
those produced by treatment of the cells with the oxidants PMS
and hydrogen peroxide (Table 1). The increase in the GSSG/
GSH ratio was accompanied by a marked and rapid increase in
PPP flux, assessed using either LC-MS/MS measurements of
6PG labeling in cells incubated with [U-13C]glucose or 13C
NMR measurements of lactate labeling in cells incubated with
[1,2-13C2]glucose (Fig. 1). DHA has been shown previously to
oxidize GSH and increase PPP flux in primary rat cortical neu-
rons (23). The increased PPP flux in cells treated with hydrogen
peroxide can be explained by a reduction in GAPDH activity
(29), whereas in cells treated with PMS or DHA, the increase in
flux is, in part, consistent with an increase in G6PDH activity
(33) (Table 1). DHA treatment of EL4 tumors also resulted in a
small but significant increase in PPP flux, as determined from
13C NMR measurements of lactate labeling in tumor extracts.
However, the increase in 6PG labeling, measured in tumor
extracts using LC-MS/MS measurements and measured non-
invasively in vivousing 13CMRS in animals injectedwith hyper-
polarized [U-2H,U-13C]glucose,was not significant (Fig. 2). The
much smaller increase in themeasured PPP flux in EL4 tumors,
as compared with the cells, reflects a lower level of oxidative
stress induced by DHA administration. This was evident from
the GSSG/GSH ratio, which was increased 4.4-fold in the
cells following DHA administration, whereas there was no sig-
nificant change in the tumors (Table 1), although the ratio in
the tumors was already10-fold higher than in the cells. Nev-
ertheless, the tumors were evidently oxidatively stressed by
DHA administration, because they showed a nearly 2-fold
increase in G6PDH activity (Table 1), consistent with the small
but significant increase in PPP flux. Radiotherapy, which gen-
erates increased levels of ROS (48), increasesG6PDHactivity in
cancer cells within 10min of exposure, and this has been attrib-
uted toROS-dependentATMkinase activation and subsequent
phosphorylation of Hsp27, which binds to G6PDH directly and
enhances its activity (33). Pathways other than the PPP can
contribute to intracellular NADPH production and thus to
reduction of GSSG and DHA, including flux through malic
enzyme (34). However, there was no evidence in this study that
NADPH came from this pathway.
Next, we determined whether the rate of DHA reduction to
AA could be used to assess the increased oxidative stress
induced by depleting the glutathione pool using BSO treat-
ment. Treatment of EL4 and Colo205 cells decreased glutathi-
one content andmarkedly reduced theGSSG/GSH ratio (Table
2), implying that the cells had responded to the oxidative stress
imposed by glutathione depletion by up-regulating those path-
ways responsible for NADPH production, which maintained
the glutathione pool in a more reduced state. Consistent with
this were measurements of increased PPP flux in EL4 cells,
assessed from measurements of both lactate and 6PG labeling.
The addition of DHA to these cells, which imposed an acute
oxidative load on the cells, resulted in a furthermarked increase
in PPP flux (Fig. 3, a and c). Colo205 cells showed less evidence
FIGURE 6.Oxidation of hyperpolarized [1-13C]AA in EL4 tumor cell suspensions. Shown is a representative time course of 13C signals from hyperpolarized
[1-13C]AA (179.0 ppm) and [1-13C]DHA (175.3 ppm) in RPMI medium (a) and in a suspension of 108 (2.5 107 ml1) intact (b) or lysed (c) EL4 cells.
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for increased PPP flux following BSO treatment, with only a
small but nevertheless significant increase at 6 h, determined
from changes in lactate labeling (Fig. 3b). The more modest
increase in PPP flux in Colo205 cells may reflect the much
higher glutathione concentration in these cells (Table 2), mak-
ing them less dependent on the PPP for buffering the GSH
concentration (see Fig. 1).
Treatment of EL4 tumor-bearing mice with BSO decreased
glutathione by 6 h after treatment and decreased the GSSG/
GSH ratio by 2-fold. This shows, similarly to EL4 cells in vitro,
that the cells had responded to the oxidative stress imposed by
BSO treatment by increasing PPP flux, the increase in NADPH
production leading to a lower steady state GSSG/GSH ratio.
Glutathione depletion also increased Grx activity at 24 h after
BSO treatment. BSO has been shown previously to decrease
glutathione levels by 40% in RIF-1 tumors 6 h after injection
(43) and to increase Grx activity, leading to increased GSSG
reduction and a decreased GSSG/GSH ratio (43). That the
tumors were oxidatively stressed is further indicated by the
increase in G6PDH activity (33) and the increased labeling of
3PG and PEP, which is indicative of oxidation and consequent
inhibition of PKM2 (49). The inferred decrease in PKM2 activ-
ity was consistent with themeasured decrease in glycolytic flux.
Although BSO treatment of Colo205 cells had effects on the
levels of glutathione similar to those observed in EL4 cells, in
Colo205 tumors, there was no significant depletion of glutathi-
one, change in theGSSG/GSH ratio, or change in enzyme activ-
ities. Nevertheless, there was an increase in PPP flux evident
from both lactate (Fig. 3g) and 6PG (Fig. 3i) labeling, which was
significant in the latter case.
Injection of hyperpolarized [1-13C]DHA into EL4 tumor-
bearing mice resulted in its reduction to [1-13C]AA, as was
observed previously (18), and this reduction was concentrated
in the tumor region (Fig. 4a). Although the data were highly
variable, oxidatively prestressing EL4 tumors by BSO treatment
resulted in a3.8-fold increase in the rate of DHA reduction at
24 h after BSO treatment. Previous studies have suggested that
the rate of DHA reduction is dependent on the levels of GSH
(19–21). These data show that in this tumor model and under
these conditions, this is not the case because at 24 h after BSO
treatment there was no significant change in the steady state
GSH concentration (Table 2). Instead, there was an increased
rate of NADPH production, resulting from increased PPP flux,
and an increase in Grx activity. This increase in the rate of
NADPH production will maintain the GSH level by increasing
the rate of GSSG reduction and increasing the rate of DHA
reduction catalyzed by GSH-dependent Grx. The estimated
rates of DHA reduction in control tumors (0.42  0.15 nmol
g1 s1) and tumors 24 h after BSO treatment (1.43  0.82
nmol g1 s1) are comparable with the rate of GSH oxidation
estimated previously in erythrocytes (0.28 M s1) (50).
Although a considerable assumption was made in estimating
the rate of DHA reduction, this is consistent withGSHbeing an
important reducing agent for DHA (see Fig. 1). At 6 h after BSO
treatment, there was no increase in the rate of DHA reduction,
although PPP flux was still elevated. However, at this time
point, the GSH concentration was decreased significantly, sug-
gesting that the effect of increased NADPH production on the
rate of DHA reduction might have been offset at 6 h by the
decrease inGSH concentration. BSO-stressedColo205 tumors,
which also showed a significant increase in PPP flux, showed a
similar pattern to EL4 tumors in the rate of DHA reduction at 6
and 24 h and decrease in GSH concentration at 6 h after BSO-
treatment, although in this case the changes were not signifi-
cant. The relative roles of GSH- and NADPH-dependent DHA
reductases in reducing DHA is debated and has been shown
previously to vary between different cell types in vitro (51, 52).
We have shown here, in tumor cells in vivo, that this may also
vary within individual tumor cell types under different meta-
bolic conditions.
While providing a potentially powerful real time measure-
ment of the reductive potential of tumors in preclinical studies,
the transient respiratory arrest induced by DHA (Fig. 5) repre-
sents a challenge to its translation to the clinic. Intravenous
injection of DHA in rats was shown previously to lead to hyper-
activity and amixed parasympathetic/sympathetic effect on the
nervous system (24). Animals in this previous study died of
respiratory failure at an LD50 of 320 mg kg1, whereas we
observed a transient respiratory arrest in mice at a dose of only
10 mg kg1, suggesting that there may be species-specific dif-
ferences in its effects. This toxicity might be overcome by pre-
injecting animals with similar doses of DHA as used for imag-
ing, because this has been shown to improve tolerance to DHA
(24) and has been used in previous preclinical studies of
hyperpolarized [1-13C]DHA (19). However, because DHA is
itself a strong oxidant and has been shown here to lead to
changes in the GSSG/GSH ratio and to increased PPP flux,
these preinjections may have the same effect as BSO and
increase the rate of reduction of hyperpolarized [1-13C]DHA
injected subsequently.
An alternative and less toxic way to assess oxidative stress in
tissues, which has clinical potential, would be to observe the
rate of AA oxidation; AA is already infused into patients,
achieving serum concentrations of 50 mM ascorbic acid (37).
However, hyperpolarized [1-13C]AA is oxidized only slowly by
intact EL4 cells (Fig. 6), and we showed previously that there
was no detectable oxidation of AA in EL4 tumors in vivo (18).
This can be explained by the slow reaction of AA with extra-
cellular H2O2 and the fact that many cell types cannot take
up AA (53). Lysis of EL4 cells resulted in an increased rate of
AA oxidation (Fig. 6), which can be explained by increased
access of AA to intracellular superoxide (O2. ), which is pro-
ducedmainly by themitochondria and NADPH oxidases and
is found mostly intracellularly (54). The addition of H2O2 to
U937 cells was shown not to oxidize AA, whereas the addi-
tion of an O2. -generating system resulted in its oxidation
(55).
In conclusion, we have shown that the rate of reduction of
hyperpolarized [1-13C]DHA is sensitive to changes in a tumor’s
capacity to resist oxidative stress and that this is related not only
to the levels of glutathione, as suggested previously (19, 20, 21),
but also to changes in PPP flux and Grx activity. The PPP pro-
vides for dynamic buffering of the GSH pool, where the addi-
tion ofDHA results in an immediate increase in theGSSG/GSH
ratio (Table 2) and an increase in PPP flux (Fig. 3, a and c).
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However, the transient toxicity of DHAwill limit if not prevent
its potential translation into the clinic.
Experimental Procedures
Materials
All materials were purchased from Sigma-Aldrich UK unless
stated otherwise.
Cell Culture and Tumor Induction
EL4 murine lymphoma cells and Colo205 human colorectal
cancer cells (ATCC, Manassas, VA) were grown in RPMI 1640
medium (Gibco, Paisley, UK) supplemented with 10% heat-in-
activated FBS (Gibco) and 2 mM L-glutamine. Colo205 cells
were genotyped by short tandem repeat (STR) genetic profiling
using the Power Plex_16HS_Cell Line panel and analyzed using
Applied Biosystems Gene Mapper ID version 3.2.1 software
(Genetica DNA Laboratories, LabCorp Specialty Testing
Group) and overlapped 100% with the Colo205 cell line
published on the DSMZ STR database. EL4 cells were STR-
genotyped by DDC Medical. EL4 tumors were induced by
implanting 5 106 cells subcutaneously into the flanks of 6–8-
week-old female C57BL/6 mice (Charles River, Ltd., Wilming-
ton, MA) and grown for10 days, when they reached1 cm3.
Colo205 tumors were induced by implanting 107 cells in 6–8-
week-old female BALB/c nude mice (Charles River) and grown
for 15 days, when they reached 1 cm3. Experiments com-
plied with licenses issued under the Animals (Scientific Proce-
dures) Act of 1986. Protocols were approved by the Cancer
Research UK Cambridge Institute Animal Welfare and Ethical
Review Body.
Measurements of PPP Flux
PPPfluxwasassessedeitherusing [1,2-13C2]glucoseandmea-
suring label incorporation into lactate using 13C NMR (27) or
using [U-13C]glucose and measuring label incorporation into
6PG using LC-MS/MS (26).
Measurements using [1,2-13C2]Glucose—EL4 cells (108)
and Colo205 cells (107) were incubated with 11 mM [1,2-
13C2]glucose for 30min at 37 °C.Mediumwas collected by cen-
trifugation and snap-frozen in liquid nitrogen. Tumor-bearing
mice were injected intravenously with 0.4 ml of 200 mM [1,2-
13C2]glucose or 0.4 ml of 200 mM [1,2-13C2]glucose and 28 mM
DHA, and the animals were sacrificed and tumors were excised
rapidly 4 min later. The tumors were then freeze-clamped
immediately with liquid nitrogen-cooled tongs, metabolites
were extracted with 7% perchloric acid, and the extracts were
neutralized subsequently with KOH. Cell medium and tumor
extracts were freeze-dried, and the lyophilized samples were
dissolved in 20 mM phosphate buffer containing 10% 2H2O and
10 mM 13C urea for 13C NMR analysis.
Measurements Using [U-13C]Glucose—EL4 and Colo205
cells (107) were incubated with 11 mM [U-13C]glucose for 30 s
and then quenched in ice-cold methanol. Tumor-bearing mice
were injected intravenously with 0.4 ml of 200 mM [U-13C]glu-
cose with or without 28 mMDHA; the animals were then sacri-
ficed, and tumors were excised rapidly at 1 min after injection
and then freeze-clamped immediately. Cells were extracted at
5  107 ml1, and tumors were excised at 50 mg ml1 in ice-
cold 75:25 methanol/acetonitrile containing 0.2% formic acid
using metal bead-containing tubes on a Precellys24 homoge-
nizer coupled to aCryolys cooler (Stretton Scientific, Stretton,
UK) at 4 °C. A second extraction was performed with 200 l of
water, and the organic and aqueous extracts were mixed. Sol-
vent was removed by evaporation, and the extracts were dis-
solved in 0.75% octylamine in HPLC grade water. LC-MS/MS
measurements of 13C-labeling of 6PG, 3PG, and PEP were
based on a method published previously (26). Analytes were
separated using octylamine/acetonitrile gradients on an
ACQUITY UPLCTM BEH130 C18 ID column (Waters, Elstree,
UK) at 30 °C and detected using a triple quadrupole TSQ
Vantage mass spectrometer with an Accela UHPLC system
(Thermo Scientific, Loughborough, UK) fitted with a HESI
probe with a source temperature of 320 °C.
Measurements of Reduced andOxidized Glutathione
GSH and GSSG were measured as described (31). Cells were
extracted at 5 107 cells ml1, and tumors were homogenized
at 50mgml1 with 25:75 water/methanol containing 0.025mM
sodium borate, 0.25 mM EDTA, and 1.25 mM 4-fluoro-7-sulfa-
moylbenzofurazan to derivatize GSH. GSH and GSSG were
separated on an Acquity UPLC HSS T3 column (Waters),
and their ions were identified from their specific mass tran-
sition in multiple reaction-monitoring mode and from their
retention time, using a triple quadrupole TSQ Vantage mass
spectrometer with Accela UHPLC system (Thermo Scien-
tific) fitted with a HESI probe with a source temperature of
320 °C. Glutathione-glycine-13C2,15N was added as an inter-
nal standard.
Enzyme Activity Assays
GAPDH (EC 1.2.1.13) activity was measured using the
KDalert kit (Thermo Fisher Scientific, Hemel Hempstead,
UK) at 22 °C. Cells were resuspended in lysis buffer at 107 cells
ml1, and tumors were freeze-clamped and extracted at 50 mg
ml1. G6PDH (EC 1.1.1.49) activity was assayed at 22 °C, as
described (56). Tumors were extracted at 200 mg ml1, and
cells were extracted at 107 cells ml1 in 50 mM HEPES buffer
containing 100 mM KCl, 10 mM phosphate buffer, 10 mM
MgCl2, 1 mM dithiothreitol, and protease inhibitor mixture
(Roche Applied Science) in a Precellys24 homogenizer coupled
to a Cryolys cooler (Stretton Scientific) at 4 °C. Protein con-
tent was measured using Direct Detect (Millipore, Billerica,
MA). Grx activity was measured using a 2-hydroxyethyl disul-
fide coupled assay (57). TrxR activity was measured in a linked
reactionwith 5,5	-dithiobis-(2-nitrobenzoic acid) andGST (EC
2.5.1.18) activitywith 2,4-dinitrochlorobenzene using assay kits
(Sigma-Aldrich). For Grx, TrxR, and GST assays, tumor and
cell samples were extracted with 50 mM potassium phosphate
buffer, pH 7, containing 0.5 mM EDTA and protease inhibitor
mixture (Roche Applied Science) in a Precellys24 homogenizer
coupled to a Cryolys cooler (Stretton Scientific) at 4 °C. Pro-
tein content was measured using Bradford reagent (Bio-Rad,
Hemel Hempstead, UK).
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Measurements of Malic Enzyme Flux
EL4 tumor-bearing mice were injected intravenously with
0.4 ml of 100 mM [3-13C]glutamine with or without 28 mM
DHA. After 4 min, tumors were rapidly excised, freeze-
clamped, extracted with 7% perchloric acid, and neutralized
with KOH. Freeze-dried extracts were dissolved in 600 l of 20
mM phosphate buffer, pH 7, with 10% 2H2O and 10 mM 13C
urea. 13CNMR spectra were acquired on a 600-MHz spectrom-
eter (Bruker BioSpin, Rheinstetten, Germany) at 300 K with a
TR of 3 s and 12,000 scans.
Hyperpolarization of [U-2H,U-13C]Glucose, [1-13C]Ascorbic
Acid, and [1-13C]Dehydroascorbic Acid
A 5 M solution of [U-2H,U-13C]glucose containing 27 mM
OX063 (GEHealthcare) and 1.3 mM gadolinium chelate (Dota-
rem, Guerbet, France) was hyperpolarized using a Hypersense
polarizer (Oxford InstrumentsMolecular Biotools Ltd., Abing-
don, UK) at1.3 K (16). Dissolution was performed after90
min using 4ml of 50mMNaCl in 2H2O containing 1mMEDTA,
yielding a final concentration of 200 mM [U-2H,U-13C]glucose.
[1-13C]AA (Omicron Biochemicals, Inc., South Bend, IN) (10
mg) was dissolved in 50 l of DMSO-d6 (Cambridge Isotope
Laboratories, Tewksbury, MA) with 14.8 mM trityl radical
(OX063; GEHealthcare) and 1.4mM gadolinium chelate (Dota-
rem). The sample was beaded in liquid nitrogen and polarized
(18). After 120 min, dissolution was performed using 3.2 ml of
H2O, and the was solution neutralized with 0.8 ml of 200 mM
phosphate buffer containing 400 mM NaCl and 1.8 mM EDTA,
giving a final concentration of 14 mM [1-13C]AA. [1-13C]AA
was oxidized to [1-13C]DHA, as described (18). A 1 M solution
of [1-13C]DHA inDMSO-d6 (Cambridge Isotope Laboratories)
containing 27mMOX063 (GEHealthcare) and 1.4mM gadolin-
ium chelate (Dotarem) was hyperpolarized as described (18).
For the imaging experiments, the DHA was dissolved in
dimethyl-13C2, sulfoxide-d6 (Isotec, Miamisburg, OH) (22).
Dissolution was performed after 90 min using 5 ml of H2O,
and the solution was neutralized with 1 ml of 200 mM phos-
phate buffer containing 400mMNaCl and 1.8mMEDTA, giving
a final [1-13C]DHA concentration of 28 mM.
13CMagnetic Resonance Spectroscopy and Spectroscopic
Imaging in Vivo
Mice were anesthetized with 2% isoflurane and placed inside
a 7 T spectrometer (Agilent, UK), and their body temperature
was maintained at 37 °C. Animals were injected via a tail vein
cannulawith 0.4ml of the dissolution fluid, anddata acquisition
started 15 s after the start of injection. Slice-selective 13C spec-
tra (8-mmslice) from the tumorwere acquired using an actively
decoupled dual-tuned 13C/1H volume transmit coil and a
20-mm 13C receive surface coil (Rapid Biomedical, Rimpar,
Germany). For experiments with glucose, spectra were
acquired with a nominal flip angle of 22°, TR 100 ms, and an
arrayed offset, where nine consecutive spectra were taken from
the lactate region and the tenth spectrumwas from the glucose
region (spectral width 6 kHz and 512 points, shift of 8 kHz
between glucose and lactate regions). For experiments with
DHA, spectrawere acquiredwith a nominal flip angle of 25°, TR
of 1 s, spectral width 6 kHz, 1024 points. For chemical shift
imaging with hyperpolarized [1-13C]DHA, 0.2 ml of the disso-
lution fluid was injected into the tail vein (19 s after the start of
dissolution), and imaging started 15 s after injection. Chemical
shift images of [1-13C]DHA and [1-13C]AAwere acquired non-
slice-selectively over the tumor region, using a 50-s hard
pulse, TR of 40 ms, echo time of 0.35 ms. Images were recon-
structed in Matlab (MathWorks, Cambridge, UK). At 5 min
after injection of hyperpolarized [1-13C]DHA, animals were
sacrificed, and the tumors were excised and immediately
freeze-clamped with liquid nitrogen-cooled tongs. Labeled
DHA was extracted with 7% perchloric acid, and extracts were
neutralized with KOH. Freeze-dried extracts were dissolved
in 20 mM phosphate buffer, pH 7, containing 10% 2H2O and 10
mM 13C urea as a chemical shift standard. 13C spectra were
acquired on a 600-MHz spectrometer (Bruker) at 300 K with a
nominal flip angle of 30°, a TR of 3 s, and 12,000 transients.
Peaks were integrated and normalized to the 13C urea standard
using Topspin version 2.1 (Bruker).
13CMagnetic Resonance SpectroscopyMeasurements on Cells
in Vitro
Two ml of dissolution fluid containing hyperpolarized
[1-13C]AA (14 mM) were injected into 2 ml of either water,
RPMImedium, hydrogen peroxide solution, or an EL4 cell sus-
pension in a 10-mm NMR tube. Spectra were acquired using a
9.4 T vertical wide bore magnet (Oxford Instruments) and a
10-mmbroadband probe (VarianNMR Instruments, Palo Alto,
CA). A total of 180 13C spectra were acquired with an 8° flip
angle pulse, TR of 500 ms, and spectral width of 16 kHz (18).
Statistical Analysis
Statistical analyses were performed using Prism version 6
(GraphPad, San Diego, CA). Unpaired two-tailed t tests were
used for all experiments, and significance was assumed at p 
0.05.
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